Advertisement

Topics

Latest "ExceleraRx Corp." News Stories

00:44 EDT 24th March 2019 | BioPortfolio

Here are the most relevant search results for "ExceleraRx Corp." found in our extensive news archives from over 250 global news sources.

More Information about ExceleraRx Corp. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about ExceleraRx Corp. for you to read. Along with our medical data and news we also list ExceleraRx Corp. Clinical Trials, which are updated daily. BioPortfolio also has a large database of ExceleraRx Corp. Companies for you to search.

Showing "ExceleraRx Corp" News Articles 1–25 of 102

Tuesday 19th March 2019

XFRA E0M: AUSSETZUNG/SUSPENSION

DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL EMBLEM CORP....


Sunday 17th March 2019

Helix BioPharma Corp. Announces Fiscal Second Quarter 2019 Results

RICHMOND HILL, Ontario, March 18, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces its financial results for its fiscal second quarter ended January 31, 2019. FINANCIAL REVIEW

Friday 15th March 2019

EVI Global Group Developments Corp. Changes to StillCanna Inc. (CSE: STIL), a Leading Extractor of CBD in Europe, and Begins Resumption of Trading

Vancouver, British Columbia - March 15, 2019 (Newsfile Corp.) (Investorideas.com Newswire) STILLCANNA INC. (FORMERLY EVI GLOBAL GROUP DEVELOPMENTS CORP.) (CSE: STIL) ("StillCanna" or the "Company") is pleased to announce the Company has completed a change of business from a mining issuer to a life sciences issuer.


Thursday 14th March 2019

Helix BioPharma Corp. Closes Private Placement, Extends Period to Exercise Warrants and Provides Corporate Update

RICHMOND HILL, Ontario, March 15, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has closed a private placement financing for gross proceeds of CAD609,450. The terms of the placement are for the purchase of uni...

Medtronic Board Appoints Andrea J. Goldsmith, Ph.D. as a New Director

DUBLIN - March 14, 2019 - Medtronic plc (NYSE:MDT) today announced that its Board of Directors has appointed Andrea J. Goldsmith, Ph.D. to the Board as an independent director, effective March 11, 2019. Dr. Goldsmith is the Stephen Harris professor in the School of Engineering at Stanford University and director of Stanford's Wireless Systems Laboratory. Her research focuses on s...

Wednesday 13th March 2019

Active Biotech has entered into an agreement regarding sale of the Company's property - extraordinary general meeting on April 4, 2019

  Lund Sweden, March 13 2019 - Active Biotech (NASDAQ STOCKHOLM: ACTI) announces that Active Biotech has entered into an agreement regarding sale of the Company's property Forskaren 1 in Lund, Sweden, with a newly formed investor collective led by the real estate company Estea AB. The purchase price amounts to SEK 275 million. Active Biotech AB (publ) indirectly owns the pro...

Monday 11th March 2019

Xbrane Biopharma informs that trading in subscription rights and interim shares is delayed and will be initiated 12 March 2019

Press release11 March 2019 The Board of Directors in Xbrane Biopharma AB (publ) ("Xbrane" or the "Company") has today been informed that the Companys subscription rights and interim shares (Ticker: XBRANE TR, ISIN: SE0012376994 and ticker: XBRANE BTA ISIN: SE0012377000) have not been registered. The error in registering the subscription rights in the sys...

Sunday 10th March 2019

CORRECTING and REPLACING - Yuhan Corp and Sorrento Therapeutics Announce Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001

SEOUL, South Korea and SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Sorrento Therapeutics, Inc. (Nasdaq: SRNE), please note that in the subheadline the year the Phase 2 study will start should be 2019, not 2020 as previously stated. The corrected release follows: Yuhan Corporation (000100.KS; Yuhan) and Sorrento Therapeutics, Inc...

Yuhan Corp and Sorrento Therapeutics Announce Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001

SEOUL, South Korea and SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) -- Yuhan Corporation (000100.KS; Yuhan) and Sorrento Therapeutics, Inc. (Nasdaq: SRNE) announced today that ImmuneOncia, a joint venture formed in September 2016, has completed the Phase 1 study of IMC-001 (also known as STI-3031), a fully human anti-PD-L1 monoclonal antibody (mAb) immune checkpoint inhibitor. This Phase 1 dose...

Thursday 7th March 2019

Xbrane publishes published prospectus in connection with fully guaranteed rights issue of approximately SEK 59 million

  Press release7 March 2019 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL Xbrane publishes published prospectus in connection ...

Wednesday 6th March 2019

Helix BioPharma Corp.: First Patient Dosed in a Phase II Randomized Study of L-DOS47 With Vinorelbine and Cisplatin

RICHMOND HILL, Ontario, March 07, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP), (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce the first patient has been successfully dosed with L-DOS47, vinorelbine and cisplatin in its Phase IIB, open-label, randomize...

Tuesday 5th March 2019

Emblem Corp. Shareholders Approve Proposed Arrangement with Aleafia Health, Announces Results of Special Meeting

TORONTO, March 06, 2019 (GLOBE NEWSWIRE) -- Emblem Corp. (TSXV: EMC, OTCQX: EMMBF) (“Emblem” or the “Company”) is pleased to announce that, at the special meeting of shareholders of Emblem held today (the “Meeting”), the shareholders of Emblem voted in favour of a special resolution to approve the proposed arrangement (the “Arrangement”) involving Emblem and Aleafia Health descr...

Matter Communications Announces Matter Health

Full-Service PR Agency Affirms Commitment to Healthcare and Bolsters Existing Practice Matter Communications – a Brand Elevation Agency specializing in PR, social media, creative services and digital marketing – today announces the launch of Matter Health, a dedicated brand for its flourishing healthcare practice.

Monday 4th March 2019

XFRA 9DV: AUSSETZUNG/SUSPENSION

DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL DELIVRA CORP...

Thursday 28th February 2019

Oxurion NV to Present Preclinical Evaluation of Plasma Kallikrein Inhibition for DME at 2019 EURETINA Winter Meeting

Leuven, Belgium, 28 February 2019 - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diabetic eye disease, announces today that it will present  at the 9th European Society of Retina Specialists (EURETINA) Winter Meeting, which is being held March 1-2, 2019 in Prague, Czech Republic at the Clarion...

Tuesday 26th February 2019

Helix BioPharma Corp. and Moffitt Cancer Center to Present at the AACR Annual Meeting 2019 in Atlanta

RICHMOND HILL, Ontario, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP), (FSE: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that together with the Moffitt Cancer Center (“Moffitt”), a poster entitled “Improving survival in pancreatic cancer usi...

Monday 25th February 2019

Zomedica Pharmaceuticals Corp. Announces Year End 2018 Financial Results

ANN ARBOR, Mich., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (TSX-V:ZOM) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today reported consolidated financial results for the year ended December 31, 2018. Amounts, unless specified otherwise, are expressed in U.S. dollars and presented under accounting principles ge...

Friday 22nd February 2019

Xbrane Biopharma releases Year-end report for 2018

Press release2019-02-22  Xbrane Biopharma AB's (publ.) ("Xbrane") Year-end report for 2018 is now available on the Company's website, www.xbrane.com. The fourth quarter 2018 in summary Revenue amounted to SEK 4,896 thousand (9,535). Gross margin amounted to 25% (24). Other operating income amounted to SEK 1,

Thursday 21st February 2019

Xbrane Biopharma AB: Alessandro Sidoli and Saeid Esmaeilzadeh decline re-election for 2019

Press release2019-02-21  Xbrane Biopharma AB (publ) ("Xbrane") has today been informed by the Nomination Committee that Alessandro Sidoli and Saeid Esmaeilzadeh have declined re-election at the Annual General Meeting (AGM) 2019. The Nomination Committee is working to find replacements for the board members and information about any new board members will be published i...

Wednesday 20th February 2019

Xbrane Biopharma AB advances the release of the Year-end report for 2018

Press release2019-02-20 Xbrane Biopharma AB hereby announce that it has been decided to advance the publication of the Year-end report for the financial year of 2018. The Year-end report will be released on Friday 22 February, 2019 instead of Thursday 28 February, 2019 as previously stated. For further information, please contact:Martin Åmark, CEO/IRM: +46(0) 763-093 777E: mart...

Tuesday 19th February 2019

EVI's (CSE: EVI) European Based Extraction Facility Initiates #Hemp Processing

Vancouver, British Columbia - February 19, 2019 (Newsfile Corp.) (Investorideas.com Newswire) EVI GLOBAL GROUP DEVELOPMENTS CORP. (CSE: EVI) ("EVI" or the "Company") is proud to announce it has begun the initial processing of hemp in its European based extraction facility.

Excelera® Specialty Pharmacy Network Welcomes St. Luke’s Health System

MINNEAPOLIS (PRWEB) February 19, 2019 ExceleraRx Corporation announced today that St. Luke’s Health System has joined the Excelera® Specialty Pharmacy Network as the network’s 22nd member and the first member in the state of Idaho. “We are very pleased to welcome St. Luke’s into our...

Thursday 14th February 2019

Martin Åmark, CEO for Xbrane Biopharma AB, becomes Head of IR for the Company

Press release2019-02-14 Martin Åmark, CEO of Xbrane Biopharma AB ("Xbrane"), will as of today also be the Head of IR for Xbrane. The reason for this is that Xbrane's current Head of IR and CFO, Susanna Helgesen, will be on parental leave on a part-time basis for a period. During the parental leave, Susanna Helgesen will remain as CFO. The finance team has also bee...

Active Biotech Year-end report January - December 2018

          Fourth quarter in brief Active Biotech communicated updated information about its financial position New data from the LEGATO-HD study presented at the 2018 HSG conference Other significant events during the January-December period Patent regarding tasquinimod for the treatment of multiple myeloma (MM) granted in the US

Wednesday 13th February 2019

Blueberries Medical Corp Enters into Letter of Intent With El Manantial Medical Centers for Rapid Product Commercialization & Patient Acquisition; To Build Two Pharmacies to Support JV

TORONTO, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (the “Company” or "Blueberries"), a leading Colombia-based licenced producer of medicinal cannabis and cannabis-derived products, has entered into a letter of intent (the “Letter Agreement”) dated February 13, 2019 for a joint venture (the “Joint Venture”) with Harmony and Life S.A.S., operating as El Ma...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks